Incretin-based therapy and risk of acute pancreatitis: A nationwide population-based case-control study

Diabetes Care

Volumn 38, Issue 6, 2015, Pages 1089-1098

  Thomsen, Reimar Wernich ^a   Pedersen, Lars ^a   Møller, Niels ^a   Kahlert, Johnny ^a   Beck Nielsen, Henning ^b   Sørensen, Henrik Toft ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYPERGLYCEMIC AGENT; INCRETIN; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; SITAGLIPTIN; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

ACUTE PANCREATITIS; ADULT; ARTICLE; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HEALTH CARE; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RISK FACTOR; ACUTE DISEASE; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGY; FACTUAL DATABASE; MIDDLE AGED; PANCREATITIS; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; DATABASES, FACTUAL; DENMARK; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; EPIDEMIOLOGIC METHODS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; MIDDLE AGED; PANCREATITIS; YOUNG ADULT;

EID: 84930629862     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2983     Document Type: Article

References (31)

1. Fakhoury WK, Lereun C, Wright D. A metaanalysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010;86:44-57.
2. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298: 194-206.
3. Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-136.
4. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 2012;61:1250-1262.
5. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diaebetes 2013;62:2595-2604.
6. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1- based therapies. Gastroenterology 2011;141: 150-156.
7. Cohen D. Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds. BMJ 2013;346:f2607.
8. Kahn SE. Incretin therapy and islet pathology: a time for caution. Diabetes 2013;62: 2178-2180.
9. Nyborg NC, Mølck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012;61:1243-1249.
10. Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med 2008;358:1970- 1971; discussion 1971-1972.
11. Ayoub WA, Kumar AA, Naguib HS, Taylor HC. Exenatide-induced acute pancreatitis. Endocr Pract 2010;16:80-83.
12. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutidedthe FDA's review of a new antidiabetic therapy. N Engl J Med 2010; 362:774-777.
13. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapiesd review of the scientific evidence. J Clin Endocrinol Metab 2011;96:2027-2031.
14. Girman CJ, Kou TD, Cai B, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 2010;12:766- 771.
15. Gonzalez-Perez A, Schlienger RG, Rodŕiguez LA. Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a populationbased cohort study. Diabetes Care 2010;33: 2580-2585.
16. Lai SW, Muo CH, Liao KF, Sung FC, Chen PC. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a populationbased cohort study in Taiwan. Am J Gastroenterol 2011;106:1697-1704.
17. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32:834-838.
18. Urushihara H, Taketsuna M, Liu Y, et al. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. PLoS ONE 2012;7:e53224.
19. Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and nonrandomised studies. BMJ 2014;348:g2366.
20. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-2354.
21. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared tometformin or glyburide. CurrMed Res Opin 2009;25:1019-1027.
22. Wenten M, Gaebler JA, Hussein M, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med 2012;29:1412-1418.
23. Faillie JL, Azoulay L, Patenaude V, Hillaire- Buys D, Suissa S. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ 2014;348:g2780.
24. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1- based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173:534-539.
25. Giorda CB, Picariello R, Nada E, et al. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study. Lancet Diabetes Endocrinol 2014;2:111-115.
26. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014;29:541-549.
27. Johannesdottir SA, Horvath-Puh o E, Ehrenstein V, Schmidt M, Pedersen L, Sørensen HT. Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions. Clin Epidemiol 2012; 4:303-313.
28. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011;39(Suppl.):30-33.
29. Leegaard A, Riis A, Kornum JB, et al. Diabetes, glycemic control, and risk of tuberculosis: a population-based case-control study. Diabetes Care 2011;34:2530-2535.
30. Floyd A, Pedersen L, Nielsen GL, Thorladcius-Ussing O, Sorensen HT. Secular trends in incidence and 30-day case fatality of acute pancreatitis in North Jutland County, Denmark: a register-based study from 1981- 2000. Scand J Gastroenterol 2002;37:1461-1465.
31. Dore DD, Chaudhry S, Hoffman C, Seeger JD. Stratum-specific positive predictive values of claims for acute pancreatitis among commercial health insurance plan enrollees with diabetes mellitus. Pharmacoepidemiol Drug Saf 2011; 20:209-213.